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Background: Anti-CD20 monoclonal antibody treatment has not only increased survival and cure rates in many
non-Hodgkin lymphomas, but also has prompted an explosion in the development of novel antibodies and
biologically active substances with specific cellular targets in the field of malignancies treatment. Since the robust
immune responses are elicited by the gene-modified T cells, gene based T cell therapy may also provide a
powerful tool for cancer immunotherapy.
Methods: In this study, we developed a vector construction encoding a chimeric T cell receptor that recognizes
the CD20 antigen and delivers co-stimulatory signals to achieve T cell activation. One non-Hodgkin lymphoma cell
line Raji cells co-cultured with peripheral blood-derived T cells were stably transfected with anti-CD20scFvFc/CD28/
CD3zeta gene or anti-CD20scFvFc gene. T cells expressing anti-CD20scFvFc/CD28/CD3zeta or anti-CD20scFvFc gene
co-cultured with CD20 positive Raji cells for different times. Cell lysis assay was carried by [
3H]TdR release assay.
The expressions of Fas, Bcl-2 and Caspase-3 of Raji cells were detected by flow cytometric. The secretion of IFN-
gamma and IL-2 in co-culture medium was tested by ELISA assay. Activity of AP-1 was analyzed by EMSA.
Results: Following efficient transduction of peripheral blood-derived T cells with anti-CD20scFvFc/CD28/CD3zeta
gene, an obvious cell lysis of Raji cells was observed in co-culture. T cells transduced anti-CD20scFvFc/CD28/
CD3zeta gene had superior secretion of IFN-gamma and IL-2 compared to T cells transduced anti-CD20scFvFc
gene. Also it led to a much stronger Fas-induced apoptosis signaling transduction in target cancer cells.
Conclusion: So adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor
activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin
lymphoma.
Background
Non-Hodgkin’s lymphoma, known as one of hematolo-
gic malignancies, is aggressive tumor with a poor prog-
nosis. Although the clinical outcome of the patients has
improved dramatically with combination chemotherapy
(CHOP and other standard protocols) and anti-CD20
monoclonal antibody therapy, non-Hodgkin’s lymphoma
has been proved to be refractory or relapse, and is ulti-
mately failure to standard treatments [1]. Therefore, var-
ious strategies have been proposed to treat Non-
Hodgkin’s lymphoma. Adoptive immunotherapy with
genetically modified T cells expressing cTCRs targeting
lymphoma-associated antigens appears to be a promis-
ing candidate. These receptors all consist of an Ag-bind-
ing domain, which is connected to a trans-membrane
domain, and fused to an intracellular signaling domain.
The extracellular Ag-binding domain most usually con-
sists of the scFv region of an antibody against the target
antigen. The common used intracellular signaling region
with the most potential is the CD3ζ chain. It had been
previously shown to be sufficient for mediating T cell
activation signals [2]. But it has recently become
increasingly clear that successful adoptive T cell therapy
requires co-stimulation: without adequate co-stimulatory
signals, resting peripheral T cells can not become acti-
vated through an intracellular ζ chain alone [3].
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express or down-regulate co-stimulatory ligands [4].
Subsequent studies found enforced expression of a
CD28 signaling domain linked to a scFv Ag-binding
region successfully provided co-stimulation. It allowed
T cells to become activated, escape pro-apoptotic condi-
tions, and preferentially expand in culture compared to
unmodified cells [5].
In this article, we describe a vector encoding a chi-
meric T-cell receptor binding the antigen CD20. The
vector construction has been described in detail by Yu
et al [6]. The advantage of this particular construction is
that it contains a co-stimulatory signaling motif from
the CD28 co-receptor. It has previously been demon-
strated to enhance T cell activation [5]. We have
recently described activity of gene-modified T cells
expressing a chimeric receptor targeting CD20 against
hematological tumors [6]. But the correlative mechan-
ism of T cells grafted with this recombinant gene to lyse
target tumor cells has not been elucidated. Our experi-
ments are designed to provide new clew for this recom-




RPMI 1640 Medium containing 2 mmol/L of L-gluta-
mine, 25 mmol/L of Hepes (GIBCO, Groud Island, NY),
and 10% FBS (Bio international New Zealand) was used
for Raji and Peripheral Blood Mononuclear Cell (PBMC)
culture.
Cell line
Fresh human peripheral mononuclear cells obtained
from normal healthy donors. Burkitt lymphoma cell line
R a j io b t a i n e df r o mA T C C .C e l l sw e r ec u l t u r e di na
humidified atmosphere containing 5% CO2 at 37°C.
Experimental protocol
The subjects were assigned into three groups: blank
group (untransfected T cells co-cultured with Raji cells),
control group (T cells transduced with anti-CD20scFvFc
receptor co-cultured with Raji cells), and experimental
group (T cells transduced with anti-CD20scFvFc/CD28/
CD3ζ receptor co-cultured with Raji cells). In each
group, 2 × 10
6 T cells were co-cultured with 2 × 10
5
Raji cells at 37°C for indicated time in 6-well plates.
Plasmid DNA
pLNCX vector containing anti-CD20 scFv was pre-
viously provided by Dr. Daming Shan (University of
Washington, USA). pBULLET vector containing anticar-
cinoembryonic antigen (anti-CEA) scFv/CD28/CD3ζ was
kindly provided by Dr. Hinrich Abken (Laboratory of
Tumor Genetic, Department of Internal Medicine, Uni-
versity of Cologne, Germany). The assembly and confir-
mation of the anti-CD20scFvFc/CD28/CD3ζ receptor
has been previously described. The recombinant plas-
mids were amplified in Escherichia coli DH5a and line-
arized by for 4 hours at 37°C incubation with 150 units
of ECOR1 (Fermentas USA) for each 100 μgp l a s m i d
DNA. The recombinant plasmids were purified by PCR
Purification Kits (Qiagen, Germany) after incubated at
65°C for 15 min. The plasmids were dissolved in TE
buffer at a concentration of 1 μg/μl and then stored at
-20°C until used for electroporation.
Generation of Recombinant Gene Modified T Cells
Heparinized peripheral blood from normal donors was
diluted 1:2 in PBS. PBMCs were isolated by density cen-
trifugation and cultured in RPMI 1640 Medium contain-
ing 10% FBS. The Medium was also supplemented with
1 μg/ml PHA-L (Roche, USA), 50 U/ml rhIL-2 (Sigma,
USA), and 30 ng/ml OKT3 (Wuhan Institute of Biologi-
cal Products, China). The recombinant human IL-2
(Sigma, USA) was added to OKT3-activated PTLs after
72 hours initial culture. The aspiration of the culture
medium (contain IL-2 and OKT3) was followed every
3 days after 10 days sustainable culture. Thus, 1 × 10
6
cells were collected and Lymphocyte subsets assay was
analyzed by flow cytometry by using Simultest Imk-
Lymphocyte Kit (BD, USA). When the rate of CD3 posi-
tive cells was above 90% among PBMCs and the amount
of cells numbers exceeded 5 × 10
7, plasmid transduction
of T cells was followed. A mixture of 100 μgp l a s m i d
DNA and 10 mg/ml salmon sperm DNA (Invitrogen
USA) was made. Then, 5 × 10
7 PBMCs were added into
RPMI 1640 Medium with the mixture. Cells suspension
was aliquoted into 0.4 ml electroporation cuvettes. The
plasmid was introduced into activated T lymphocytes by
electroporation by using a Multiporator (Bio-Rad Gene
Pulser Xcell USA) set at 300 V, 2 ms. Cells were incu-
bated at room temperature for 5 min, resuspended in
culture medium (contain 10% FBS, IL-2 and OKT3),
and then incubated in an incubator at 37°C in 5% CO2.
G418 (cALBio-chem USA) at an active concentration of
800 μg/ml was added to culture medium after electro-
poration for 48 hours. PBMCs were selected by G418
for 7 days prior to cloning. G418-resistant PBMCs were
successfully transfected with recombinant gene.
Western blot analysis
Whole cells lysates of untransfected and transduced
with two types of recombinant gene were generated by
lysis of 2 × 10
7 washed cells in 1 mL of Protein Extrac-
tion Reagent (Thermo Scientific USA). Protein electro-
phoresis, transferring to membrane and blotting were
carried out according to standard protocol.
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Microscopic analysis was performed to study morpholo-
gical alteration of Raji cells. Therefore, experimental and
blank groups incubated at 37°C for indicated time in 6-
well assay plate were investigated by using microscope
(Leica).
Cell lysis assay
DNA fragmentation induced by gene modified T cells in
Raji cells was employed by [
3H]TdR release assay. 2 × 10
6
Raji cells were preincubated with 20 μci [
3H]TdR (GE
h e a l t h c a r e )a t3 7 ° Cf o r4h o u r s .E a c h2×1 0
5 Raji cells
were co-cultured with 2 × 10
6 gene modified or untrans-
fected T cells at 37°C in 6-well plates. 100 μLc e l l - f r e e
supernatants were harvested and mixed with 1 ml scintil-
lation liquid after incubation for indicated time at 37°C.
Radioactivity was detected by scintillation counting
(Beckman). The percentage of specific lysis was calcu-
lated as 100 × [(experimental release)-(spontaneous
release)/(maximum release)-(spontaneous release)].
Spontaneous release of [
3H]TdR by target cells was evalu-
ated in wells containing medium alone. Maximum release
value was obtained from target cells incubated with
2% SDS.
Flow cytometric analysis to determine expression of Fas,
Bcl-2 and Caspase-3
Cells from three groups were fixed and permeabilized by
Cytofix/Cytoperm reagent (Becton Dickinson PharMin-
gen) after harvested from 6-well assay plates. Then they
were indicated by Cy5-conjugated CD20 antibody and a
panel of antibodies including PE-conjugated Fas antibody,
FITC-conjugated Bcl-2 antibody, and PE-conjugated Cas-
pase-3 antibody for analysis of cell immunophenotypes.
Cells were washed twice, resuspended in 300 μl PBS con-
taining 3% paraformaldehyde, and analyzed by using a
FACSCalibur (Becton Dickinson) after incubation for
25 min at 37°C.
Analysis of cytokine production
Cells in three groups were cultured in 6-well assay
plates for 24 hours. Thus, cell supernatants were col-
lected, and ELISA assay for IFN-gamma and IL-2 was
carried out by using the R&D Systems kit.
Electrophoretic Mobility Shift Assay (EMSA)
Cells were harvested and washed twice with PBS before
staining with Cy5-labeled anti-CD3 antibody and further
separated by a FACSCalibur (Becton Dickinson). The
nuclear fractionation of T cells was carried out according
to the manufacturer’s instructions by using the NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce
Biotechnology). AP-1 DNA binding was assayed using
5′-CGCTTGATGAGTCAGCCGGAA-3′ oligonucleotide
as a probe. The double stranded, AP-1 oligonucleotide
was labeled with biotin. Binding reactions were carried
out for 20 min at room temperature in the presence of
50 ng/μl poly(dI-dC), 0.05% Nonidet P-40, 5 mmol/L
MgCl2, 10 mmol/L EDTA, and 2.5% glycerol in 1 × bind-
ing buffer (LightShift™ chemiluminescent EMSA kit,
Pierce) using 2 μl of biotin, end labelled target DNA and
5 μg of nuclear extract. Unlabelled target DNA was
added to 20 μl of binding reaction where indicated as a
negative control. Assays were loaded onto native 6%
polyacrylamide gels pre-electrophoresed for 30 minutes
in 0.5 × Tris borate/EDTA and electrophoresed at 100 V
for 50 minutes. The DNA is then transferred to a positive
nylon membrane, UV-crosslinked, probed with horserad-
ish peroxidase conjugated streptavidin (LightShift™
chemiluminescent EMSA kit) according to the manufac-
turer’s instructions.
Statistical analysis
The results of each series of experiments (performed in
triplicates) were expressed as the mean values ± stan-
dard deviation of the mean (SD). Statistical significance
of differences between groups was analyzed by using
ANOVA analysis. P < 0.05 was considered statistically
significant.
Results
Assembly of anti-CD20 scFvFc/CD28/CD3ζ
The whole DNA fragment coding for anti-CD20scFvFc/
CD28/CD3ζ was shown in Fig. 1A. It was confirmed by
restriction digestion mapping and DNA sequencing.
Expression of anti-CD20scFvFc/CD28/CD3ζ in PBMCs
T Lymphocyte Subsets of PBMCs was analyzed by flow
cytometry. As showed in Fig. 1B, the CD3 positive cell
population of PBMCs was above 90% and the CD8 posi-
tive CTL cells accounted for the majority of PBMCs
population. Cell lysates from transduced peripheral
blood T lymphocytes were probed with an anti-CD3ζ
mAb to detect the endogenous CD3ζ and the recombi-
nant CD3ζ in transduced PBMCs. As shown in Fig. 1C,
a 21 KDa band corresponding to wild-type CD3ζ and a
68 KDa band consistent with anti-CD20scFvFc/CD28/
CD3ζ were present in cell lysates of transduced periph-
eral blood T lymphocytes after 7 days culture.
Morphology
The Raji cells adhered to T cells, but kept integrity of
cell morphology after 2 hours co-culture with anti-
CD20scFvFc/CD28/CD3ζ transduced T cells. Raji cells
in experimental group presented prominent cell swel-
ling, intramural thickening of granule and cell lysis after
12 hours co-culture (Fig. 1D-a). Raji cells in experimen-
tal group showed vast cell death associated with cell
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whole process, the modified T cells kept in a good
integrity of cell morphology.
Target cell lysis by T cells
The specific killing of CD20-positive Raji cells by T cells
transduced anti-CD20scFvFc/CD28/CD3ζ or anti-
CD20scFvFc recombinant gene was showed in cytotoxi-
city assays. But T cells transduced anti-CD20scFvFc/
CD28/CD3ζ gene had superior ability to lyse the CD20-
positive tumor cells compared to T cells transduced
anti-CD20scFvFc gene. There was slight lysis of Raji
cells co-cultured with untransduced T cells (Fig. 1E).
Flow cytometric analysis to determine expression of Fas,
Bcl-2 and Caspase-3
Although Fas initially had a low basal expression in Raji
cells, its expression sharply ascended in experimental
and control group after 12 hours co-culture with gene
modified T cells. Its expression had a statistically signifi-
cant difference between experimental and control group
at 12-hour time point. After that, the difference became
undetectable due to the restriction of the rates of posi-
tive expression analyzed by flow cytometric (Fig. 2A).
Raji cells originally had a high basal expression of Bcl-
2 response to the positive expression rates above 95%.
An obvious downward trend of Bcl-2 expression of Raji
cells was observed in experimental and control group
compared to blank group. It was noteworthy that Bcl-2
expression of Raji cells in experimental group had an
aggressively decline from 12 to 48 hours. During this
process, the experimental group showed obviously sig-
nificant difference compared to the counterparts in con-
trol and blank group (P < 0.05) (Fig. 2B).
It appeared to be a marked increase in Caspase-3
expression of Raji cells in experimental and control
Figure 1 A: Schematic diagram of the anti-CD20scFvFc-pLNCX and anti-CD20scFvFc/CD28/CD3ζ pLNCX, LTR: long term repeat, Neo:
neomycin, CMV: cytomegalovirus. B: The CD3, CD4 and CD8 antigens on surface of PBMCs, which incubated for 10 days after stimulation by
PHA-L, OKT3 and IL-2 were analyzed by flow cytometry. A life gate was set around CD3 positive cells; only those cells expressing this membrane
protein were included, and 20,000 events were analyzed. C: PBMCs grafted with anti-CD20scFvFc/CD28/CD3ζ after selected by G418 for 7 days
and analysis of PBMCs grafted with anti-CD20scFvFc/CD28/CD3ζ by Western blot. D-a:PBMCs grafted with anti-CD20scFvFc/CD28/CD3ζ co-
culture with Raji cells for 12 hours. D-b: PBMCs grafted with anti-CD20scFvFc/CD28/CD3ζ co-culture with Raji cells for 24 hours. E: Cell lysis
evaluated by [3H]TdR release assay. (In experimental group, *represents p < 0.05 compared to control group at the same time point).
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Page 4 of 8Figure 2 The co-cultured PBMCs and Raji cells were separated by CD20 expressing. The CD20 antigens on surface of Raji cells were
analyzed by flow cytometry. A life gate was set around CD20 positive cells; only those cells expressing this membrane protein were included,
and 20,000 events were analyzed. A: The expression of Fas in Raji cells co-cultured with anti-CD20scFvFc/CD28/CD3ζ, anti-CD20scFvFc
transduced T cells or untransduced T cells were analyzed by flow cytometry. B: The expression of Bcl-2 in Raji cells co-cultured with anti-
CD20scFvFc/CD28/CD3ζ, anti-CD20scFvFc transduced T cells or untransduced T cells were analyzed by flow cytometry. C: The expression of
Caspase-3 in Raji cells co-cultured with anti-CD20scFvFc/CD28/CD3ζ, anti-CD20scFvFc transduced T cells or untransduced T cells were analyzed
by flow cytometry. (In experimental group, *represents p < 0.05 compared to control group at the same time point).
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tal group led to a significantly greater proportion of
Caspase-3 expression compared to control group and
blank group after 12 hours co-culture (Fig. 2C).
Secretion of IFN-gamma and IL-2
T cells co-cultured with Raji cells could induce a sus-
taining secretion of IFN-gamma in a time-dependent
manner. Comparing to control and blank group, IFN-
gamma secreted in experimental group had an express
go up at 12-hour time point and was obvious superior
in subsequent time points (Fig. 3A).
As the time go by, the secretion of IL-2 in supernatant
of experimental group had an obvious increase trend. It
had obvious superior statistically significant differences
compared to other two groups from initial co-culture
(Fig. 3B).
AP-1 binding in gene modified T cells
Due to it has been demonstrated that there is a strong
cooperativity between transcription factors that bind to
the IL-2 promoter, in particular, activating protein 1
(AP-1) in regulating IL-2 transcription. To determine if
gene modified T cells increase IL-2 secretion levels by
altering the DNA binding activity of the transcription
factor, AP-1, EMSA analysis was performed. Our results
demonstrated that gene modified T cells altered the
DNA binding activity of AP-1. AP-1 binding in gene
modified T cells of experimental group had distinctly
superior compared to control group (Fig. 3C).
Discussion
The anti-CD20 monoclonal antibody has demonstrated
its efficacy in non-Hodgkin’s lymphoma treatment.
However, despite the success of Rituximab treatment,
Figure 3 A: Raji cells were co-cultured with anti-CD20scFvFc/CD28/CD3ζ, anti-CD20scFvFc transduced T cells or untransduced T cells.
Supernatants from these cultures were tested by ELISA for IFN-gama. B: Supernatants from these cultures were tested by ELISA for IL-2. C: AP-1
DNA binding were measured by EMSA. (In experimental group, *represents p < 0.05 compared to control group at the same time point).
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early relapse of the original disease occurs in around
50% of the patients [7]. Although the precise mechanism
of resistance to Rituximab is not fully understood, it is
suggested that the patient-specific microenvironment of
the lymphoma is related to cancer resistance. The signif-
icance of the microenvironment in Rituximab-induced
cell death is indirectly observed by differential responses
to Rituximab therapy in different subtypes of CD20-
positive lymphomas (which have unique microenviron-
ments) [7]. Malignant tumor cells can receive additional
survival signals in some unique microenvironments, as
some lymph node compartments (germinal centres)
[3,8]. Moreover, the myeloid-lineage cells infiltrating
some of these lymphomas may provide trophic stimuli
to the malignant cells [9]. Exposure to these pro-survival
signals makes these cells less sensitive to the anti-CD20
antibody. Accordingly, attempts have been made to
improve the therapeutic efficacy and overcome some
resistance. For example, combination therapy is a
method to overcome some resistance to regular che-
motherapy in some patients who over-express Bcl-2
[10]. Meanwhile, other methods are made to improve
ADCC by immunostimulatory molecules, such as some
cytokines, or enhancing CDC by down-regulation of
complement regulatory proteins [7]. Since T cells can
transfer to lymph nodes, lyse multiple targets, proliferate
in response to antigenic stimulation, and persist in the
tumor-bearing host for prolonged periods of time, the
modified T cells expressing chimeric T cell receptors
targeting lymphoma-associated antigen appear to be a
promising alternative [11,12]. Also recent innovations
including enhanced co-stimulation, exogenous cytokine
administration, and use of memory T cells promise to
overcome many of the limitations and pitfalls initially
encountered with anti-CD20 mAb [3].
In this study, modified T cells were investigated to
express an engineered anti-CD20scFvFc/CD28/CD3ζ
receptor lysed CD20 positive Raji cells with higher effi-
ciency, and it was capable to produce superior amounts
of IFN-gamma and IL-2 compared to anti-CD20scFvFc
transduced T cells. IFN-gamma produced by cytotoxic
T lymphocyte is a critical cytokine for exerting antiviral,
antimicrobial effect, and immune surveillance of tumors,
which could directly inhibit proliferation and induce
apoptosis of some malignancies in vivo and vitro
through elusive mechanisms [13]. IL-2 is pivotal for sur-
vival of antigen-selected cytotoxic T cells via the activa-
tion of the expression of specific genes and development
of T cell immunologic memory. Moreover, IL-2 has
been shown to work in synergy with production of
immunoglobulins and induce the proliferation and dif-
ferentiation of natural killer cells [14]. It has been pub-
lished that secretion of IFN-gamma and IL-2 plays an
important role for a long lasting anti-tumor response of
modified T cells [15]. Hence, superior secretion of IFN-
gamma and IL-2 by anti-CD20scFvFc/CD28/CD3ζ
recombinant gene modified T cells compared to anti-
CD20scFvFc transduced T cells may achieve the dual
benefit of enhanced ADCC and adaptive immune system
engagement.
The B-cell restricted cell surface phosphor-protein
CD20 is involved in many cellular signaling events
including proliferation, differentiation, and apoptosis. So
Rituximab can trigger and modify various intracellular
signaling pathways in non-Hodgkin lymphoma B-cell
lines, resulting in induction of apoptosis and chemosen-
sitization. It is reported that the Fas-induced apoptotic
pathway is involved in Rituximab mediated signaling
transduction. This pathway activated by Fas is referred
to as two type pathways. In type I pathway, initiator
Caspases cleave and activate executor Caspases-3
directly. In type II pathway, also called mitochondrial
pathway, is controlled by Bcl-2 family. The two path-
ways converge at the end by activating executor Cas-
pases-3. Bcl-2 can inhibit apoptosis by preventing
disruption of the mitochondria and the subsequent
release of Cytochrome c. Consequently, overexpression
of Bcl-2 has a protective effect against Fas-induced
apoptosis in malignancies. It indicates potential thera-
peutic strategy for lymphoma treatment. Also, preclini-
cal data from lymphoma cell lines and primary tumor
samples indicate high efficacy of Bcl-2 inhibitor ABT-
737 against lymphoma [16]. Caspase-3, a member of the
Caspase family, has been found to integrate upstream
signals into final execution of apoptosis. Its activity is an
important predictor of apoptosis. Studies have shown
unanimous results and clear evidence for this relation-
ship. As expected, Rituximab-mediated apoptosis is
thought to be a consequence of Caspase-3 activation,
and data from patients with CLL also support this con-
cept [17]. In this study, we observed that anti-
CD20scFvFc/CD28/CD3ζ receptor grafted T cells could
result in greater up-regulation of Fas expression, down-
regulation of Bcl-2 and Caspase-3 activation in Raji cells
compared to anti-CD20scFvFc receptor grafted T cells.
From the secretion of cytokine and expression of apop-
tosis-related proteins in target cells, it manifested CD3ζ
and CD28 co-stimulation signaling could synergistically
enhance the target cytotoxicity and induction of apopto-
sis by gene modified T cells. Therefore this is expected
to enhance the efficacy of the recombinant receptor
approach, which can be used in the cellular immu-
notherapy of malignant diseases. Although we suppose
it may overcome some limitations of anti-CD20 mono-
clonal antibody treatment from the promising results in
present study, we anticipate the refinements in substan-
tial research to validate its potential value in future.
Zheng et al. Journal of Experimental & Clinical Cancer Research 2010, 29:121
http://www.jeccr.com/content/29/1/121
Page 7 of 8Conclusion
Our findings suggest that in addition to secretion of
IFN-gamma and IL-2 according to the specific cytotoxi-
city against CD20 positive tumor cells by anti-
CD20scFvFc/CD28/ζ receptor grafted T cells, Fas/FasL
apoptotic pathway also contributes to anti-CD20scFvFc/
CD28/ζ gene modified adoptive T cells-mediated cyto-
toxicity in vivo.
Abbreviations
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